Abstract Introduction Five-year survival after continuous-flow left ventricular assist device (LVAD) implantation has improved substantially, resulting in a growing population of ultra-long-term LVAD patients, defined as 5 years and longer survival on LVAD. Remarkably, determinants of mortality beyond the 5-year landma...
C. Velásquez-Silva, W. H. Nielsen, C. Møller et al.· ESC Heart Failure· 0 citations
OBJECTIVES
This study aimed to assess the prognostic value of Six-minute Walk Distance (6MWD) in stable HeartMate 3 (HM3) recipients.
METHODS
Data from patients with available 6MWD at six months post-implant were obtained from the prospective, multicenter ELEVATE registry. Overall survival and adverse event rates wer...
W. H. Nielsen, F. Gustafsson, S. Shaw et al.· Interdisciplinary cardiovasc...· 0 citations
BACKGROUND
SGLT2 inhibitors (SGLT2i) reduce mortality in left heart failure. In pulmonary arterial hypertension (PAH), preclinical data suggest SGLT2i improve right ventricular function through metabolic modulation and inhibition of vascular remodeling via smooth muscle cell pathways. The DAPAH trial evaluated whether...
M. Ersbøll, J. Kjærgaard, K. Waidtløw et al.· The Journal of Heart and Lun...· 1 citation
Abstract Introduction Ambulatory low cardiac output state (LCOS) is a known but poorly described heart failure (HF) phenotype. We aimed to investigate the prevalence, clinical markers, and prognostic importance of ambulatory LCOS. Methods Consecutive ambulatory patients with HF and reduced left ventricular ejection fra...
B. Hansen, T. Deis, Cecilie Müller Ralsted et al.· ESC Heart Failure· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.